Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2017

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

The following table presents the impact the discontinuation and market withdrawal of Ionsys had on the Company’s statement of operations for the three and six months ended June 30, 2017:

Operating expenses:
Cost of product revenue	$	8,458
Asset impairment charges	264,097
Research and development	1,032
Selling, general and administrative	3,434
Total operating expenses	277,021
Loss from operations	(277,021		)
(Loss) income from continuing operations before income taxes	(277,021		)
Benefit (provision) for income taxes	—
Net (loss) income from continuing operations	$	(277,021	)

The following table presents the consideration received, major classes of assets sold and the gain recognized on the sale of the Non-Core ACC Products:

	(in thousands)
Sale price:
Cash	$	263,807
Contingent purchase price from sale of business	65,700
Total sale price	329,507
Assets:
Inventory	2,184
Intangibles	5,210
Goodwill	33,812
Total assets sold	41,206
Gain on sale of business	$	288,301

The following table presents key financial results of the Hemostasis Business included in “(Loss) income from discontinued operations, net of tax” for the three and six months ended June 30, 2016:

	Three Months Ended June 30,			Six Months Ended June 30,
	2016			2016
Net product revenues	$	(12	)	$	50
Operating expenses:
Cost of product revenue	(589		)	1,704
Research and development	(27		)	119
Selling, general and administrative	(15		)	678
Total operating expenses	(631		)	2,501
Income (loss) from operations	619			(2,451		)
Gain from sale of business	—			1,004
Other expense, net	—			(39		)
Income (loss) from discontinued operations before income taxes	619			(1,486		)
Benefit for income taxes	—			—
(Loss) income from discontinued operations, net of tax	$	619		$	(1,486	)